Compare UE & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UE | DYN |
|---|---|---|
| Founded | 2014 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 2014 | 2020 |
| Metric | UE | DYN |
|---|---|---|
| Price | $21.07 | $15.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 16 |
| Target Price | $22.00 | ★ $38.63 |
| AVG Volume (30 Days) | 937.3K | ★ 1.6M |
| Earning Date | 05-13-2026 | 06-03-2026 |
| Dividend Yield | ★ 4.01% | N/A |
| EPS Growth | ★ 23.33 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $471,935,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $28.32 | ★ N/A |
| Revenue Growth | ★ 6.06 | N/A |
| 52 Week Low | $15.66 | $7.01 |
| 52 Week High | $21.87 | $25.00 |
| Indicator | UE | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 59.68 | 43.72 |
| Support Level | $18.53 | $14.67 |
| Resistance Level | $21.68 | $19.65 |
| Average True Range (ATR) | 0.40 | 0.95 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 50.71 | 52.77 |
Urban Edge Properties is a real estate investment trust principally focused on the management and development of retail real estate properties in urban communities in the U.S. Having originally been created to hold the majority of Vornado Realty Trust's shopping center businesses, Urban Edge's asset portfolio is mostly composed of shopping centers and malls in terms of total square footage. The company's holdings include necessity and convenience-oriented retailers, such as department stores, grocers, health clubs, and restaurants. Urban Edge's properties are mainly located in the New York City metropolitan region and within the DC to Boston corridor. The company generates nearly all of its revenue through the collection of rent from a large number of tenants.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.